The nucleus was supposed to be about information. DNA storage, transcription, gene regulation — the nuclear envelope exists to separate the genome from the metabolic chaos of the cytoplasm. The cytoplasm is where energy gets made. The nucleus is where instructions get read. The division of labor is foundational to cell biology.
A team led by researchers at the Max Planck Institute (Nature Communications, 2026) profiled the native chromatome — the full set of proteins attached to chromatin — across 10 healthy tissue types and 44 cancer cell lines. They found more than 200 metabolic enzymes sitting directly on the DNA. Not transiently visiting. Not passively diffusing. Stably associated with chromatin, comprising about 7 percent of all chromatin-bound proteins.
These are not obscure enzymes. They include components of oxidative phosphorylation — the process that generates most of the cell's ATP, supposedly confined to mitochondria. Enzymes that synthesize nucleotides for DNA repair. Enzymes from pathways that have no obvious nuclear function. The nucleus, it turns out, runs its own small metabolic network. The researchers call it a “mini metabolism.”
The structural finding is about IMPDH2. When the researchers confined this enzyme to the nucleus, it maintained genome stability. When they confined the identical enzyme to the cytoplasm, it influenced entirely different cellular pathways. Same molecule. Same amino acid sequence. Same three-dimensional fold. Different address, different job.
This is not dual function in the usual sense — two binding sites, two conformations, two substrates. IMPDH2 doesn't change. Its context changes. The nuclear environment — the chromatin landscape, the local metabolite concentrations, the surrounding protein complexes — determines which of the enzyme's capabilities gets expressed. The molecule is a set of possibilities. The address selects among them.
The cancer data makes this concrete. Different tissues and different cancers display distinct patterns of nuclear metabolic enzymes — a “nuclear metabolic fingerprint.” Oxidative phosphorylation enzymes appear commonly on breast cancer chromatin but are largely absent from lung cancer chromatin. The fingerprint is tissue-specific and disease-specific, meaning whatever the nucleus is doing with these enzymes, it is doing it selectively.
One puzzle remains unresolved. Many of the enzymes found on DNA are significantly larger than the nuclear pore complex is believed to permit. The standard model of nuclear import has a size limit. These enzymes exceed it. They are present anyway. Either the size limit is wrong, or cells have an unknown transport mechanism for moving large metabolic proteins into the nucleus. The infrastructure for the mini metabolism includes logistics that haven't been discovered yet.
The through-claim: the enzyme doesn't change — the address changes what the enzyme does. Function is not a property of the molecule. It is a property of the molecule's location. The nucleus isn't borrowing cytoplasmic tools for a side job. It is running a metabolic program that exists because the same enzymes, placed differently, become different machines.